Pharmacokinetics, absorption, distribution, metabolism and excretion of the MEK inhibitor zapnometinib in rats.

Autor:	Füll Y; Department of Immunology, Interfaculty Institute for Cell Biology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.; Atriva Therapeutics GmbH, Tuebingen, Germany., Wallasch C; Atriva Therapeutics GmbH, Tuebingen, Germany., Hilton A; Labcorp Early Development Laboratories Ltd., Huntingdon, United Kingdom., Planz O; Department of Immunology, Interfaculty Institute for Cell Biology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.; Atriva Therapeutics GmbH, Tuebingen, Germany.
Jazyk:	angličtina
Zdroj:	Frontiers in pharmacology [Front Pharmacol] 2022 Dec 05; Vol. 13, pp. 1050193. Date of Electronic Publication: 2022 Dec 05 (Print Publication: 2022).
DOI:	10.3389/fphar.2022.1050193
Abstrakt:	Zapnometinib is a MEK inhibitor currently under clinical development for the treatment of COVID-19 and influenza. Zapnometinib has both antiviral and immunomodulatory effects. Information concerning the absorption, distribution, metabolism, and excretion of the compound following single oral doses of 30 mg/kg [ 14 C]-zapnometinib to rats was required to support pharmacology and toxicology studies in animals and clinical studies in man. As part of the development and safety assessment of this substance, zapnometinib was radioactively labeled and used for the investigation of time-dependent plasma concentrations, the rates and routes of excretion, the extent and time-course of compound distribution in body tissues, the metabolite profiles in plasma, urine and feces and the chemical nature of its metabolites. The present study reveals a rapid but low absorption of zapnometinib from the gastrointestinal tract, with more than 90% of the compound being excreted within 48 h, mainly via feces. Whole body autoradiography confirms that zapnometinib was rapidly and widely distributed, with greatest concentrations in the circulatory and visceral tissues. Maximum plasma and tissue concentrations occurred between two and 8 h post dose. Penetration into the brain was low, and elimination from most tissues almost complete after 168 h. Metabolic profiles showed that the main clearance routes were metabolism via oxidative reactions and glucuronidation. These results further strengthen the knowledge of zapnometinib with respect to the clinical development of the drug. Competing Interests: OP and CW are shareholders of Atriva Therapeutics GmbH. OP is a consultant for Atriva Therapeutics GmbH. CW and YF are employees of Atriva Therapeutics GmbH. AH is an employee of Labcorp Early Development Laboratories Ltd. (Copyright © 2022 Füll, Wallasch, Hilton and Planz.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu